Novo Nordisk launches a $56.50 per share bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and highlighting the strategic value of Metsera's GLP-1 pipeline.
Novo Nordisk launches a $56.50 per share bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and highlighting the strategic value of Metsera's GLP-1 pipeline.